Comparative Study on Three Open Access Drug Label Databases: Drugs@FDA, FDA Online Label Repository and DailyMed
10.6039/j.issn.1001-0408.2018.01.32
- VernacularTitle:Drugs@FDA、FDA Online Label Repository和DailyMed三大开放获取药品说明书数据库的比较研究
- Author:
Qi SUN
1
;
Jiying HAO
;
Juntao MA
;
Zhibing YANG
Author Information
1. 解放军医学图书馆知识服务中心
- Keywords:
Drug label;
Database;
Drugs@FDA;
FDA Online Label Repository;
DailyMed
- From:
China Pharmacy
2018;29(1):131-134
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To provide reference for pharmacy staff to choose different drug label databases according to different needs.METHODS:The information organization mode of the three open access drug label databases that included Drugs@FDA,FDA Online Label Repository and DailyMed had been collected and analyzed comparatively from three aspects:retrieval function settings,search results display,data resources and service targets.RESULTS & CONCLUSIONS:In respect of retrieval function,DailyMed provided the most abundant retrieval functions than others.In respects of search results display,DailyMed provided the highest degree of formatted data,followed by FDA Online Label Repository,while Drugs@FDA provided semi-formatted data.Three databases provided the functions of page replication and printing,among which the interface of DailyMed was friendlier and the content of DailyMed was more open;it provided all the download functions.In respects of data resources and service targets,developers of Drugs@FDA and FDA Online Label Repository were FDA,and that of DailyMed was National Library of Medicine (NLM).The data sources used by Drugs@FDA were the drug labels after strict approval by FDA,and the description of drug information by Drugs@FDA was the most comprehensive.FDA Online Label Repository was the original drug labels submitted by the manufacturer to FDA,which was the latest content,and even included unlisted drugs.The data sources of DailyMed were from the information listed on the drug package,and included the information of drug label which was listed but not approved strictly;it covered most comprehensive drugs.
